What Neuland Laboratories does

Neuland Laboratories Limited is a Hyderabad-headquartered, publicly listed (NSE: NEULANDLAB) Active Pharmaceutical Ingredient (API) manufacturer and Contract Development and Manufacturing Organization (CDMO) founded in 1984. The company operates three US FDA-inspected manufacturing facilities in Telangana, India (Bonthapally, Pashamylaram, and Gaddapotharam) supported by an R&D Centre, and serves more than 500 pharmaceutical and biotech customers across 80+ countries. Neuland's offering spans three product lines: (1) generic APIs split into Prime (high-volume mature molecules) and Specialty (lower-volume, complex) categories, (2) end-to-end CDMO services covering custom development, process optimization, analytical testing, and regulatory CMC support from Pre-IND through commercial supply, and (3) custom peptide development and manufacturing via Solid-Phase Peptide Synthesis (SPPS) and Liquid-Phase Peptide Synthesis (LPPS) capabilities, including a new commercial peptide module targeting GLP-1 and innovator biotech demand.

The underlying technology platform is built on complex small-molecule and peptide chemistry, anchored by proprietary capabilities in SPPS and LPPS, Green Chemistry by Design (GCbD) process integration aligned with Quality by Design (QbD), and the NeuACTS sustainable supplier engagement program. Quality and regulatory infrastructure is the company's structural backbone: cGMP certifications from US FDA, EMA, EDQM, TGA, PMDA, CFDA, Health Canada, KFDA, ANVISA, Cofepris, and the German Health Authority, plus ISO 9001/14001/27001 and OHSAS 18001, enable global commercial supply. Neuland employs approximately 2,000 people and draws on India's deep life-sciences talent pipeline to maintain a stated 30-40% cost advantage versus Western CDMOs.

Commercially, Neuland runs a B2B enterprise field-sales model with regional offices in India, Japan, the US (Princeton, NJ), and Switzerland, complemented by participation in industry events such as BOS Basel and CPHI NorthAmerica. Pricing is quote-based and project-tied, with multi-year contracts typical for CDMO engagements; revenue streams are project-based rather than subscription or license-recurring. Recent financial performance demonstrates sharp inflection: FY26 total income reached Rs 20,531 million with EBITDA of Rs 6,034 million, while Q4FY26 revenue grew 136% YoY and the CDMO segment grew 366% YoY, accompanied by EBITDA margin expansion to 40.5%. Capacity additions (120.5 KL expansion at Unit I for Rs 143.4 crore; 6,370 L new peptide module with ~USD 30 million in firm commitments) and the April 2026 leadership transition to Saharsh Davuluri as CEO indicate an aggressive scaling posture targeting a top-five global API CDMO position within a decade.

Name

Neuland Laboratories

Legal name

Neuland Laboratories Ltd.

Website

https://neulandlabs.com

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Neuland Laboratories is a Hyderabad-based publicly listed API manufacturer and CDMO serving 500+ pharma and biotech customers across 80+ countries from three US FDA-inspected facilities, offering generic APIs, custom CDMO services, and peptide manufacturing including SPPS/LPPS capabilities.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Industrial Organic Chemicals (2860)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Small-Molecule API Commercial Manufacturing (HLAGAHAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Active pharmaceutical ingredients
• Contract development manufacturing
• Peptide manufacturing services
• Generic API manufacturing
• Pharmaceutical CDMO services

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generic API Manufacturing: Development and manufacturing of non-exclusive Active Pharmaceutical Ingredients including Prime APIs (large volume, mature molecules) and Specialty APIs (lower volume, complex molecules with less competition) for quality-conscious customers globally
2. CDMO Services (Contract Development and Manufacturing): End-to-end continuum of customized NCE development services from lab to commercial supply, including process development, process optimization, analytical testing, and regulatory support. The CDMO segment showed 366% YoY growth in Q4FY26
3. Peptide Development and Manufacturing: Custom peptide synthesis services including process development and large-scale cGMP manufacturing for clinical trials and commercial production

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Neuland Laboratories develops, manufactures, and supplies Active Pharmaceutical Ingredients (APIs) for global pharmaceutical and biotech companies. Its offering includes generic APIs (Prime and Specialty), end-to-end Contract Development and Manufacturing Organization (CDMO) services spanning process development, analytical development, and commercial cGMP manufacturing for New Chemical Entities (NCEs), and custom peptide synthesis and large-scale peptide manufacturing (SPPS and LPPS).

Differentiator

Problem solved

Functional benefit

Products and services

• Generic APIs

Quantifiable outcome

• Q4FY26 revenue grew 136% YoY with PAT growth of 666%
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• LIR Life SciencescoreStrategic or Co-development Partner · 5 February 2026LIR Life Sciences has commenced Project Phase 2 peptide design activities with Neuland Laboratories under their existing services agreement. The collaboration focuses on design and optimization of next-generation cell-penetrating peptides for LIR's transdermal delivery platform. The program involves systematic structure-activity relationship analysis to develop third-generation peptide candidates with improved performance and manufacturability potential.

Scale indicators14 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Divi's Laboratories: Leading Indian API manufacturer with significant CDMO/custom synthesis operations serving global pharma customers. Most direct comparable given its API focus, India base, US FDA-inspected facilities, and growing CDMO/peptide exposure.
• Laurus Labs: Indian API and CDMO company with strong small-molecule synthesis capabilities and growing peptide/biologics CDMO services. Direct peer in Indian API space with similar customer base of global pharma and biotech clients.
• Syngene International: India-headquartered contract research and manufacturing organization (CRAM) offering integrated drug discovery, development, and manufacturing services. Direct peer in Indian CDMO space with comparable global pharma customer base.
• Jubilant Pharmova: Indian pharma company with significant CDMO operations including radiopharmaceuticals, APIs, and contract manufacturing. Comparable in CDMO service offering and customer mix of global innovators.
• Piramal Pharma Solutions: Global CDMO offering integrated API and finished dosage form development and manufacturing services. Direct peer in CDMO space with comparable complex chemistry capabilities and customer base of innovator pharma companies.
• Bachem: Swiss-headquartered global leader in peptide and oligonucleotide CDMO services. Most direct peer in the peptide CDMO segment where Neuland is investing heavily, targeting similar biotech and GLP-1 customers.
• Cambrex: Specialty CDMO focused on small-molecule API development and manufacturing from clinical to commercial scale. Direct peer in small-molecule CDMO with comparable complex chemistry capabilities and pharma/biotech customer base.

Broad incumbents

• Lonza Group: World's largest CDMO offering small molecules, biologics, cell and gene therapy services. Broad incumbent in the CDMO space with overlapping API and peptide capabilities but serving as part of a much wider portfolio.
• Aurobindo Pharma: Large Indian pharmaceutical company with significant API manufacturing operations serving global markets. Broader incumbent in Indian API space with wider generics portfolio and USFDA-inspected facilities.
• Dr. Reddy's Laboratories: Major Indian pharmaceutical company with API manufacturing operations and growing CDMO services. Broader incumbent with overlapping API capabilities and similar regulatory compliance footprint across global markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuland Laboratories